Radiology Department, Santa Croce e Carle Hospital, Via Coppino 26, 12100, Cuneo, Italy,
Radiol Med. 2015 Apr;120(4):361-8. doi: 10.1007/s11547-014-0447-3. Epub 2014 Sep 23.
The aim of the paper is to report the clinical outcome after prostatic artery embolisation (PAE) in 13 consecutive patients with benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS).
From May 2012 to October 2013, we performed PAE in 13 consecutive patients (mean age 75.9 years) with BPH and LUTS and refractory to medical therapy; seven patients had an indwelling bladder catheter. Clinical follow-up (mean follow-up time 244 days) was performed using the international prostate symptoms score (IPSS), quality of life (QoL), the international index of erectile function (IIEF), blood prostatic specific antigen (PSA) testing and transrectal prostatic ultrasound (US) scan with volume and weight calculation at 3, 6 and 12 months. Pre-procedural CT angiography (CTA) was done for vascular mapping. Embolisation was performed using Embosphere (300-500 micron). Technical success was defined when selective prostatic arterial embolisation was completed in at least one pelvic side. Clinical success was defined when symptoms and quality of life were improved.
PAE was technically successful in 12/13 patients (92%). In one patient, PAE was not performed because of tortuosity and atherosclerosis of iliac arteries. PAE was completed bilaterally in 9/13 (75%) patients and unilaterally in three (27%). All patients removed the bladder catheter from 4 days to 4 weeks after PAE. We obtained a reduction in IPSS (mean, 17.1 points), an increase in IIEF (mean, 2.6 points), an improvement in Qol (mean, 2.6 points) and a volume reduction (mean, 28%) at 12 months.
Consistent with the literature, our experience showed the feasibility, safety and efficacy of PAE in the management of patients with LUTS related to BPH. PAE may play an important role in patients in whom medical therapy has failed, who are not candidates for surgery or transurethral prostatic resection (TURP) or refuse any surgical treatment. Larger case series and comparative studies with standard TURP can confirm the validity of the technique.
本文旨在报告 13 例连续接受前列腺动脉栓塞术(PAE)治疗的良性前列腺增生(BPH)和下尿路症状(LUTS)患者的临床结果。
2012 年 5 月至 2013 年 10 月,我们对 13 例(平均年龄 75.9 岁)接受 BPH 和 LUTS 治疗且对药物治疗无效的患者进行了 PAE;其中 7 例患者留置膀胱导管。通过国际前列腺症状评分(IPSS)、生活质量(QoL)、国际勃起功能指数(IIEF)、前列腺特异性抗原(PSA)检测和直肠前列腺超声(US)扫描(3、6 和 12 个月时计算体积和重量)进行临床随访(平均随访时间 244 天)。在进行血管造影前进行 CT 血管造影(CTA)以进行血管成像。使用 Embosphere(300-500 微米)进行栓塞。当至少在一侧骨盆完成选择性前列腺动脉栓塞时,定义为技术成功。当症状和生活质量得到改善时,定义为临床成功。
13 例患者中有 12 例(92%)PAE 技术成功。1 例患者由于髂动脉迂曲和动脉粥样硬化而未进行 PAE。13 例患者中有 9 例(75%)双侧完成 PAE,3 例(27%)单侧完成。所有患者在 PAE 后 4 天至 4 周内拔除膀胱导管。我们在 12 个月时获得了 IPSS(平均 17.1 分)、IIEF(平均 2.6 分)、Qol(平均 2.6 分)的改善和体积减少(平均 28%)。
与文献一致,我们的经验表明,PAE 治疗 BPH 相关 LUTS 具有可行性、安全性和有效性。PAE 可能在药物治疗失败、不适合手术或经尿道前列腺切除术(TURP)或拒绝任何手术治疗的患者中发挥重要作用。更大的病例系列和与标准 TURP 的比较研究可以证实该技术的有效性。